|
| Category | FY | Funding IC | Project Number | Sub Project # | Project Title | PI Name | Org Name | State / Country | Amount |
|
Pediatric Cancer
|
2018
|
NCI
|
5U01CA199221-05
|
|
Osteosarcoma: Patient Derived Xenograft Preclinical Testing
|
GORLICK, RICHARD
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$136,071
|
|
Pediatric Cancer
|
2018
|
NCI
|
1K22CA214849-01
|
|
The role of the histone chaperone Chaf1b in sustaining the Hoxa9-driven AML differentiation block
|
BLANCO, MARIO
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$191,970
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA197313-03
|
|
Functional Dissection of the K27M Histone Mutation In Gliomagenesis
|
BECHER, OREN
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
IL
|
$334,865
|
|
Pediatric Cancer
|
2018
|
NINR
|
5R01NR014248-04
|
|
A Clinic-Based Interdisciplinary Intervention for Parents of Children with Cancer
|
PAI, AHNA
|
CINCINNATI CHILDRENS HOSP MED CTR
|
OH
|
$614,963
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA132640-17
|
|
Role of heat shock factors (Hsfs) in tumorigenesis
|
MIVECHI, NAHID
|
AUGUSTA UNIVERSITY
|
GA
|
$270,000
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA190964-04
|
|
Role of IKAROS in the Biology and Therapy of High-Risk Precursor B-Cell Leukemia
|
VAN ETTEN, RICHARD
|
UNIVERSITY OF CALIFORNIA-IRVINE
|
CA
|
$544,106
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA194058-03
|
|
Painted erythrocyte carriers for therapy of acute myeloid leukemia
|
SIMBERG, DIMITRI
|
UNIVERSITY OF COLORADO DENVER
|
CO
|
$352,151
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA201230-04
|
|
The role of H3K79 methylation in IDH-mutant leukemia
|
BERNT, KATHRIN
|
CHILDREN'S HOSP OF PHILADELPHIA
|
PA
|
$438,616
|
|
Pediatric Cancer
|
2018
|
NICHD
|
5R01HD086195-03
|
|
Smart targeting nano-theranostics for image-guided drug delivery to pediatric brain tumors
|
LI, YUANPEI
|
UNIVERSITY OF CALIFORNIA AT DAVIS
|
CA
|
$325,775
|
|
Pediatric Cancer
|
2018
|
NCI
|
5P30CA014089-43
|
5249
|
Core-007
|
FARNHAM, PEGGY
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$567,359
|
|
Pediatric Cancer
|
2018
|
NCI
|
5P30CA014089-43
|
5251
|
Core-009
|
FARNHAM, PEGGY
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$649,099
|
|
Pediatric Cancer
|
2018
|
NCI
|
5P30CA014089-43
|
8290
|
Tumor Microenvironment Research Program (Project-003)
|
DECLERCK, YVES
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$70,375
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA185301-04
|
|
Enhancing NK Cell Activity by Dietary Diphyllin Lignans for Cancer Prevention
|
YU, JIANHUA
|
OHIO STATE UNIVERSITY
|
OH
|
$352,275
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R00CA181500-05
|
|
The Role of Protein Tyrosine Phosphate PRL3 in Leukemia Development
|
BLACKBURN, JESSICA
|
UNIVERSITY OF KENTUCKY
|
KY
|
$248,999
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA174683-05
|
|
Comprehensive Approach to Improve Medicine Adherence in Pediatric Leukmia
|
BHATIA, SMITA
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
AL
|
$597,219
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA090668-15
|
|
FLT3 Tyrosine Kinase Inhibitors as Therapy for Leukemia
|
SMALL, DONALD
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$291,600
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA195519-03
|
|
Image-guided irradiation safely intensifies HSCT regimen for refractory leukemia
|
FORMAN, STEPHEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
CA
|
$238,425
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA201184-03
|
|
Biologic and Therapeutic Significance of miR-155 in AML
|
MARCUCCI, GUIDO
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
CA
|
$549,553
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA190617-04
|
|
Itraconazole Analogues to Treat Medulloblastoma
|
HADDEN, MATTHEW
|
UNIVERSITY OF CONNECTICUT STORRS
|
CT
|
$382,211
|
|
Pediatric Cancer
|
2018
|
NCI
|
5P30CA016058-42
|
5094
|
Clinical Protocol and Data Management (Core 017)
|
DEVINE, STEVEN
|
OHIO STATE UNIVERSITY
|
OH
|
$491,214
|
|
Pediatric Cancer
|
2018
|
NINDS
|
5K08NS099427-02
|
|
Targeting ATRX-Deficient Pediatric GBM
|
KOSCHMANN, CARL
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$163,263
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA158073-07
|
|
The Role of ATM in Suppression of Lymphomas
|
ZHA, SHAN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$380,000
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA178380-05
|
|
Leukotriene-Induced Nestin Expression Promotes Medulloblastoma Tumorigenesis
|
YANG, ZENG-JIE
|
RESEARCH INST OF FOX CHASE CAN CTR
|
PA
|
$379,725
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA172408-05
|
|
Role of Asxl1 in normal hematopoiesis and pathogenesis of myeloid malignancies
|
YANG, FENG-CHUN
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
FL
|
$318,513
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R03CA212800-02
|
|
Advancing Treatments for Pediatric Craniopharyngioma (ATPC): Preliminary Assessment of the Cyst Fluid Inflammatory Milieu
|
HANKINSON, TODD
|
UNIVERSITY OF COLORADO DENVER
|
CO
|
$77,750
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA204979-02
|
|
Mechanisms of inv(16) acute myeloid leukemia
|
CASTILLA, LUCIO
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
MA
|
$436,263
|
|
Pediatric Cancer
|
2018
|
NICHD
|
5R21HD087760-02
|
|
Targeting SHP2 phosphatase for chemoprevention of leukemic progression in Noonan syndrome
|
QU, CHENG-KUI
|
EMORY UNIVERSITY
|
GA
|
$234,000
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA142928-09
|
|
Targeting the Kinome in Neurofibromatosis type 1
|
CHERNOFF, JONATHAN
|
RESEARCH INST OF FOX CHASE CAN CTR
|
PA
|
$434,625
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA211711-02
|
|
APPLYING ERROR-CORRECTED SEQUENCING TO DETECT MINIMAL RESIDUAL IN THE AAML 1031 STUDY
|
DRULEY, TODD
|
WASHINGTON UNIVERSITY
|
MO
|
$352,587
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA212649-02
|
|
Personalized vaccine for patients with AML
|
AVIGAN, DAVID
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
MA
|
$721,179
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA169784-05
|
|
Genetic Dissection of Acute Myeloid Leukemia.
|
AIFANTIS, IANNIS
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
NY
|
$355,993
|
|
Pediatric Cancer
|
2018
|
NHLBI
|
5K08HL135434-02
|
|
Targeting SETBP1 in Myeloproliferative Disorders
|
STIEGLITZ, ELLIOT
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
CA
|
$179,928
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA142874-08
|
|
Targeting PML for Leukemia Therapy
|
PANDOLFI, PIER PAOLO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
MA
|
$457,619
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R03CA212924-02
|
|
Developing a Decision Aid for Adolescent and Young Adult Female Cancer Survivors Considering Future Family-Building after Treatment
|
BENEDICT, CATHERINE
|
FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
|
NY
|
$82,500
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA211328-02
|
|
Regulation of the LIN28/let-7 pathway in cancer
|
GREGORY, RICHARD
|
BOSTON CHILDREN'S HOSPITAL
|
MA
|
$404,888
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA142665-08
|
|
Glucocorticoids in Lymphoblastic Leukemia
|
RELLING, MARY
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$487,994
|
|
Pediatric Cancer
|
2018
|
NCI
|
5P30CA014236-44
|
5328
|
Neuro-Oncology Research Program
|
KASTAN, MICHAEL
|
DUKE UNIVERSITY
|
NC
|
$40,785
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA190980-04
|
|
Contribution of development and age to breast cancer etiology
|
BARCELLOS-HOFF, MARY
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
CA
|
$569,421
|
|
Pediatric Cancer
|
2018
|
NCI
|
5P30CA023108-39
|
5364
|
Protocol Review and Monitoring (PRMS)
|
LEWIS, LIONEL
|
DARTMOUTH COLLEGE
|
NH
|
$62,026
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA211044-02
|
|
Off-the-shelf engineered NK cells for the treatment of AML
|
REZVANI, KATY
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$366,000
|
|
Pediatric Cancer
|
2018
|
NCI
|
5P30CA006516-53
|
5399
|
Program 4: Leukemia
|
EBERT, BENJAMIN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$74,743
|
|
Pediatric Cancer
|
2018
|
NCI
|
5P30CA006516-53
|
5409
|
Program 30: Neuro-Oncology
|
STILES, CHARLES
|
DANA-FARBER CANCER INST
|
MA
|
$75,340
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA187219-03
|
|
Peptide vaccine immunotherapy for children with recurrent low-grade astrocytomas
|
POLLACK, IAN
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$352,786
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA204093-02
|
|
A First-in-Human Pilot Study of 18F-MFBG Imaging for Evaluation of Neuroblastoma
|
PANDIT-TASKAR, NEETA
|
SLOAN-KETTERING INST CAN RESEARCH
|
NY
|
$392,078
|
|
Pediatric Cancer
|
2018
|
NHLBI
|
5R01HL130034-03
|
|
The Cebpa Enhancer in Normal Hematopoiesis and Progression to AML
|
FRIEDMAN, ALAN
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$405,000
|
|
Pediatric Cancer
|
2018
|
NIGMS
|
5R01GM117093-03
|
|
Kinase-mediated assembly of the mRNA entry channel in 40S ribosomes
|
KARBSTEIN, KATRIN
|
SCRIPPS FLORIDA
|
FL
|
$416,481
|
|
Pediatric Cancer
|
2018
|
NHLBI
|
5R01HL117976-05
|
|
Epithelial mechanisms of inducible resistance to AML-associated pneumonia
|
EVANS, SCOTT
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$400,000
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA204915-02
|
|
Dissecting the Pathogenesis of Ewing Sarcoma with Integrative Genomics
|
STEGMAIER, KIMBERLY
|
DANA-FARBER CANCER INST
|
MA
|
$396,547
|
|
Pediatric Cancer
|
2018
|
NIGMS
|
5R01GM121414-02
|
|
Defining the Role of BPTF Epigenetic Reader Domains in Cancer
|
POMERANTZ, WILLIAM
|
UNIVERSITY OF MINNESOTA
|
MN
|
$314,246
|
|
Pediatric Cancer
|
2018
|
NCI
|
5P30CA008748-52
|
7572
|
Research Pharmacy
|
MULLER, RAYMOND
|
SLOAN-KETTERING INST CAN RESEARCH
|
NY
|
$206,346
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA204158-02
|
|
Vitamin D and Photodynamic Therapy for Human Skin Cancer (SCC and BCC)
|
MAYTIN, EDWARD
|
CLEVELAND CLINIC LERNER COM-CWRU
|
OH
|
$463,965
|
|
Pediatric Cancer
|
2018
|
NCI
|
5P01CA084203-14
|
5337
|
Project 1: Small Molecule Enhancers of Photodynamic Therapy for Skin Cancer
|
MAYTIN, EDWARD
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$181,731
|
|
Pediatric Cancer
|
2018
|
NCI
|
5K08CA212279-02
|
|
Understanding How Ciliary Hedgehog Signaling Causes Medulloblastoma
|
RALEIGH, DAVID
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
CA
|
$177,124
|
|
Pediatric Cancer
|
2018
|
NIGMS
|
5R01GM118578-02
|
|
Genetics-guided Individualization of Thiopurine Therapy
|
YANG, JUN
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$558,496
|
|
Pediatric Cancer
|
2018
|
NICHD
|
5R01HD079568-04
|
|
MICROBLEEDS AS A MARKER OF RADIATION-INDUCED BRAIN INJURY IN PEDIATRIC PATIENTS
|
LUPO, JANINE
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
CA
|
$502,673
|
|
Pediatric Cancer
|
2018
|
NINDS
|
5K08NS083626-04
|
|
Elucidating Signaling Pathways for GABA-A Receptor Alpha5 in an Aggressive Subtype of Medulloblastomas
|
SENGUPTA, SOMA
|
EMORY UNIVERSITY
|
GA
|
$188,396
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA154923-07
|
|
Genetics of Rhabdomyosarcoma
|
LANGENAU, DAVID
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$406,125
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R35CA197695-02
|
|
Translating genomic discoveries to improved outcomes for high risk acute leukemia
|
MULLIGHAN, CHARLES
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$1,077,000
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA192924-04
|
|
CSF2 receptor mediated actions in t(8;21) leukemia
|
ZHANG, DONG-ER
|
UNIVERSITY OF CALIFORNIA, SAN DIEGO
|
CA
|
$342,403
|
|
Pediatric Cancer
|
2018
|
NCI
|
5U24CA055727-24
|
|
Childhood Cancer Survivor Study
|
ARMSTRONG, GREGORY
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$4,218,764
|
|
Pediatric Cancer
|
2018
|
NCI
|
5K08CA181340-05
|
|
Targeting Chromatin Modifications in Leukemia with Trisomy 21
|
LANE, ANDREW
|
DANA-FARBER CANCER INST
|
MA
|
$128,526
|
|
Pediatric Cancer
|
2018
|
NINDS
|
5R01NS094218-02
|
|
Focal Sustained Release Chemotherapy-Loaded Biomaterials at Tumor Sites
|
KAPLAN, DAVID
|
TUFTS UNIVERSITY MEDFORD
|
MA
|
$342,745
|
|
Pediatric Cancer
|
2018
|
NIGMS
|
1P20GM121322-01A1
|
8733
|
Immunometabolic regulation of leukemic niche-donor cell interaction
|
DU, WEI
|
WEST VIRGINIA UNIVERSITY
|
WV
|
$255,080
|
|
Pediatric Cancer
|
2018
|
NCI
|
5K07CA174728-05
|
|
A Novel Mobile Health Fitness Program for AYA Childhood Cancer Survivors
|
DEVINE, KATIE
|
RBHS -CANCER INSTITUTE OF NEW JERSEY
|
NJ
|
$164,851
|
|
Pediatric Cancer
|
2018
|
NCI
|
5P30CA062203-21
|
8736
|
Clinical Protocol and Data Management (CPDM)
|
O'BRIEN, SUSAN
|
UNIVERSITY OF CALIFORNIA-IRVINE
|
CA
|
$262,668
|
|
Pediatric Cancer
|
2018
|
NIDDK
|
5R01DK105014-04
|
|
Role of the Hypoxia-Inducible Factor-1alpha in Myelodysplastic Syndromes
|
HUANG, GANG
|
CINCINNATI CHILDRENS HOSP MED CTR
|
OH
|
$351,000
|
|
Pediatric Cancer
|
2018
|
NCI
|
2P01CA013106-46A1
|
5085
|
Project 4: Transcriptional Coactivators and Enhancers in Human Cancer
|
VAKOC, CHRISTOPHER
|
COLD SPRING HARBOR LABORATORY
|
NY
|
$553,842
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA201225-03
|
|
Leukemia Specific Splice Isoforms as Neo-Antigens for T-Cell Immunotherapy
|
ARMISTEAD, PAUL
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$490,809
|
|
Pediatric Cancer
|
2018
|
NCI
|
2P50CA107399-11A1
|
5662
|
Therapy-related leukemia following autologous transplantation for lymphoma
|
BHATIA, SMITA
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
CA
|
$676,409
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R00CA188679-04
|
|
Regulation of Apoptotic Priming and Competence in Healthy and Cancerous Cells
|
SAROSIEK, KRISTOPHER
|
HARVARD SCHOOL OF PUBLIC HEALTH
|
MA
|
$249,000
|
|
Pediatric Cancer
|
2018
|
NIEHS
|
5R01ES024373-04
|
|
Autophagy and GG-NER in UVB-induced skin cancer
|
HE, YU-YING
|
UNIVERSITY OF CHICAGO
|
IL
|
$355,500
|
|
Pediatric Cancer
|
2018
|
NIEHS
|
5U13ES026496-03
|
|
Childhood Leukemia International Consortium Scientific Annual Meetings
|
METAYER, CATHERINE
|
UNIVERSITY OF CALIFORNIA BERKELEY
|
CA
|
$15,000
|
|
Pediatric Cancer
|
2018
|
NINDS
|
5R01NS088219-04
|
|
Glycolytic regulation of cerebellar development and medulloblastoma tumorigenesis
|
GERSHON, TIMOTHY
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$327,837
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA159859-07
|
|
Mouse models to discover new drivers of medulloblastoma
|
WECHSLER-REYA, ROBERT
|
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
|
CA
|
$746,845
|
|
Pediatric Cancer
|
2018
|
NCI
|
5F30CA213878-02
|
|
Co-Evolution of the CD8+ T Cell Repertoire and AML In the Setting of Immunotherapy
|
GEORGE, JASON
|
RICE UNIVERSITY
|
TX
|
$49,524
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA084628-26
|
|
Telomerase in Development, Senescence and Neoplasia
|
DEPINHO, RONALD
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$616,000
|
|
Pediatric Cancer
|
2018
|
NCI
|
1R01CA221957-01
|
|
Genomic and functional characterization of a panel of neuroblastoma patient-derived xenografts and cell lines
|
REYNOLDS, CHARLES
|
TEXAS TECH UNIVERSITY HEALTH SCIS CENTER
|
TX
|
$553,437
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA202261-02
|
|
Improving HPV Vaccination Delivery in Pediatric Primary Care: The STOP-HPV Trial
|
SZILAGYI, PETER
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$625,767
|
|
Pediatric Cancer
|
2018
|
NCI
|
1R01CA222012-01
|
|
Innovative Pain and Symptom Management Program for Children with Cancer
|
FORTIER, MICHELLE
|
UNIVERSITY OF CALIFORNIA-IRVINE
|
CA
|
$716,535
|
|
Pediatric Cancer
|
2018
|
NCI
|
1R01CA222590-01
|
|
Developing a novel therapeutic strategy for overcoming TKI resistance in ALL
|
LI, SHAOGUANG
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
MA
|
$487,847
|
|
Pediatric Cancer
|
2018
|
NCI
|
1R01CA222349-01
|
|
Non-canonical Caspase-8 Activation on Autophagosomal Membranes
|
WANG, HONG-GANG
|
PENNSYLVANIA STATE UNIV HERSHEY MED CTR
|
PA
|
$348,696
|
|
Pediatric Cancer
|
2018
|
NCI
|
1R01CA224381-01
|
|
Mechanistic investigation of malignant rhabdoid childhood tumor using the Drosophila model
|
DENG, WU-MIN
|
FLORIDA STATE UNIVERSITY
|
FL
|
$348,397
|
|
Pediatric Cancer
|
2018
|
NCI
|
1R01CA223674-01
|
|
Engineering knotted peptide therapeutics for pediatric brain tumor patients
|
OLSON, JAMES
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$690,368
|
|
Pediatric Cancer
|
2018
|
NHLBI
|
5R01HL136504-02
|
|
TEMPORAL CHANGES IN MECHANISMS OF HSC SELF-RENEWAL AND MYELOID LEUKEMOGENESIS
|
MAGEE, JEFFREY
|
WASHINGTON UNIVERSITY
|
MO
|
$381,250
|
|
Pediatric Cancer
|
2018
|
NCI
|
1K08CA222699-01
|
|
Targeting MerTK as an immunotherapeutic strategy in acute myeloid leukemia
|
LEE SHERICK, ALISA
|
UNIVERSITY OF COLORADO DENVER
|
CO
|
$175,285
|
|
Pediatric Cancer
|
2018
|
NCI
|
1K08CA222684-01
|
|
Targeting mitochondrial one carbon folate metabolism for novel T-cell acute lymphoblastic leukemia therapy
|
PIKMAN, YANA
|
DANA-FARBER CANCER INST
|
MA
|
$177,120
|
|
Pediatric Cancer
|
2018
|
NHLBI
|
1K08HL140138-01
|
|
Investigating the Mechanisms of Cohesinopathy in Myelodysplastic Syndromes
|
TOTHOVA, ZUZANA
|
DANA-FARBER CANCER INST
|
MA
|
$171,720
|
|
Pediatric Cancer
|
2018
|
NIEHS
|
5R21ES027418-02
|
|
Training Pediatric Health Care Providers as a Primary Information Source for Communicating Environmental Risks for Breast Cancer
|
SILK, KAMI
|
MICHIGAN STATE UNIVERSITY
|
MI
|
$186,090
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA213131-02
|
|
Targeting Transcriptional Regulators for Immunotherapy of Acute Myeloid Leukemia
|
KORTYLEWSKI, MARCIN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
CA
|
$430,377
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R00CA181496-05
|
|
Modeling p53 Mutant-Associated Cancer With LFS Patient-Derived iPSCs
|
LEE, DUNG-FANG
|
UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
|
TX
|
$237,098
|
|
Pediatric Cancer
|
2018
|
NCI
|
5K08CA194162-04
|
|
The Role of LIN28B Signaling in Mediating the Oncogenic Phenotype in Neuroblas
|
SCHNEPP, ROBERT
|
EMORY UNIVERSITY
|
GA
|
$168,264
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA076167-15
|
|
Genetic Analysis of Myeloproliferative Disease
|
COWELL, JOHN
|
AUGUSTA UNIVERSITY
|
GA
|
$307,800
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA197336-03
|
|
Transcriptional CDKs as therapeutic targets in MYC-dependent cancers
|
GEORGE, RANI
|
DANA-FARBER CANCER INST
|
MA
|
$407,748
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA080728-18
|
|
Dissection of eIF4E dependent mRNA export
|
BORDEN, KATHERINE
|
UNIVERSITY OF MONTREAL
|
CANADA
|
$210,799
|
|
Pediatric Cancer
|
2018
|
NCI
|
5U10CA180884-05
|
|
COG NCTN Solid Malignancy Integrated Translational Science Center
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
PA
|
$192,024
|
|
Pediatric Cancer
|
2018
|
NIGMS
|
1R01GM126363-01
|
|
Mechanistic Studies of Type II Topoisomerases and Topoisomerase-Targeted Agents
|
OSHEROFF, NEIL
|
VANDERBILT UNIVERSITY
|
TN
|
$302,225
|
|
Pediatric Cancer
|
2018
|
NCI
|
5K08CA201591-02
|
|
Targeting the ARHGAP25 pathway in acute myelogenous leukemia stem cells
|
WANG, LEO
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
CA
|
$169,560
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA204378-02
|
|
Improving treatment of cardiovascular risk factors in childhood cancer survivors
|
CHOW, ERIC
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$734,545
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA193677-03
|
|
Role of enhancer elements in regulating prometastatic transcriptional programs in osteosarcoma
|
SCACHERI, PETER
|
CASE WESTERN RESERVE UNIVERSITY
|
OH
|
$362,569
|
|
Pediatric Cancer
|
2018
|
NHLBI
|
5R01HL131744-03
|
|
Molecular Genetics of Dyskeratosis Congenita
|
BERTUCH, ALISON
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$512,031
|
|
Pediatric Cancer
|
2018
|
NCI
|
1R21CA223439-01
|
|
Targeting MCJ/DNAJC15 and the mitochondrial electron transport chain in acute myeloid leukemia
|
DEGREGORI, JAMES
|
UNIVERSITY OF COLORADO DENVER
|
CO
|
$163,459
|
|
Pediatric Cancer
|
2018
|
NCI
|
1R21CA209298-01A1
|
|
A novel genetic pathway for survival of B-lymphoblastic leukemia-initiating cells
|
LI, SHAOGUANG
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
MA
|
$218,588
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA151898-08
|
|
CRLF2 signaling in B-cell acute lymphoblastic leukemia
|
WEINSTOCK, DAVID
|
DANA-FARBER CANCER INST
|
MA
|
$392,969
|
|
Pediatric Cancer
|
2018
|
NCI
|
5P30CA021765-39
|
6700
|
Cancer Prevention & Control
|
GILBERTSON, RICHARD
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$588,588
|
|
Pediatric Cancer
|
2018
|
NCI
|
5P30CA021765-39
|
6701
|
Developmental Biology and Solid Tumor
|
GILBERTSON, RICHARD
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$987,656
|
|
Pediatric Cancer
|
2018
|
NCI
|
5P30CA021765-39
|
6702
|
Hematalogical Malignancies
|
GILBERTSON, RICHARD
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$695,190
|
|
Pediatric Cancer
|
2018
|
NCI
|
5P30CA021765-39
|
6703
|
Neurobiology and Brain Tumors
|
GILBERTSON, RICHARD
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$325,818
|
|
Pediatric Cancer
|
2018
|
NCI
|
5P30CA021765-39
|
6704
|
Shared Resource Group1: Genomics and Statistics
|
GILBERTSON, RICHARD
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$188,783
|
|
Pediatric Cancer
|
2018
|
NCI
|
5P30CA021765-39
|
6707
|
Data and Safety Monitoring/NIH Policy
|
GILBERTSON, RICHARD
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$153,118
|
|
Pediatric Cancer
|
2018
|
NCI
|
5P30CA021765-39
|
6708
|
Protocol Review and Monitoring System
|
GILBERTSON, RICHARD
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$255,148
|
|
Pediatric Cancer
|
2018
|
NCI
|
5P30CA021765-39
|
6709
|
Early Phase Clinical Research Support
|
GILBERTSON, RICHARD
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$256,190
|
|
Pediatric Cancer
|
2018
|
NCI
|
5P30CA021765-39
|
6710
|
Senior Leadership
|
GILBERTSON, RICHARD
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$371,954
|
|
Pediatric Cancer
|
2018
|
NCI
|
5P30CA021765-39
|
6711
|
Planning and Evaluation
|
GILBERTSON, RICHARD
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$75,221
|
|
Pediatric Cancer
|
2018
|
NCI
|
5P30CA021765-39
|
6713
|
Administration
|
GILBERTSON, RICHARD
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$258,153
|
|
Pediatric Cancer
|
2018
|
NCI
|
5P30CA021765-39
|
6716
|
Transdisciplinary Collaboration and Coordination
|
GILBERTSON, RICHARD
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$319,532
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA183874-04
|
|
Mechanism of tumor promotion by the H3K9 histone demethylase KDM3A in Ewing Sarcoma.
|
JEDLICKA, PAUL
|
UNIVERSITY OF COLORADO DENVER
|
CO
|
$355,706
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA204586-03
|
|
Yap and beta-catenin interactions in liver: Implications in Pathophysiology
|
MONGA, SATDARSHAN
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$416,268
|
|
Pediatric Cancer
|
2018
|
NCI
|
5U10CA180866-05
|
|
Network Lead Academic Participating Site Grant from the Roswell Cancer Inst.
|
LEVINE, ELLIS
|
ROSWELL PARK CANCER INSTITUTE CORP
|
NY
|
$585,200
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA195642-04
|
|
Triad1 regulates myelopoiesis and functions as a leukemia suppressor
|
EKLUND, ELIZABETH
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
IL
|
$353,419
|
|
Pediatric Cancer
|
2018
|
NCI
|
5F30CA196095-03
|
|
The CARMA3/Bcl10/MALT1 signalosome in osteosarcoma metastasis
|
MCAULEY, JAMES
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$49,524
|
|
Pediatric Cancer
|
2018
|
NCI
|
5F30CA192832-04
|
|
ATR: a novel therapeutic target for medulloblastoma identified by its role in cerebellar development
|
LANG, PATRICK
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$41,614
|
|
Pediatric Cancer
|
2018
|
NCI
|
5F32CA206418-03
|
|
Epigenetic Mechanisms of Oncohistone Detoxification
|
DIEHL, KATHARINE
|
PRINCETON UNIVERSITY
|
NJ
|
$59,038
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R44CA213595-02
|
|
Rapid detection of minimal residual disease in acute myeloid leukemia from peripheral blood
|
MULLER, ROLF
|
BIOFLUIDICA, INC
|
NC
|
$712,071
|
|
Pediatric Cancer
|
2018
|
NEI
|
5K08EY027464-02
|
|
Developing alternative approaches to reduce retinal toxicity and prevent vision loss in the treatment of intraocular retinoblastoma
|
DANIELS, ANTHONY
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
TN
|
$191,925
|
|
Pediatric Cancer
|
2018
|
NCI
|
5K99CA207731-02
|
|
Discovery of Synthetic Lethal Targets for Recurrent Epigenetic Mutations in Acute Myeloid Leukemia
|
THOMAS, DANIEL
|
STANFORD UNIVERSITY
|
CA
|
$173,448
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA188520-04
|
|
Genome maintenance by Hdacs1,2 and their inhibition for Pre-B leukemia therapy
|
BHASKARA, SRIVIDYA
|
UNIVERSITY OF UTAH
|
UT
|
$340,838
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA194057-04
|
|
Metabolic pathways in leukemia
|
SCHUETZ, JOHN
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$410,606
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA190843-04
|
|
A Label-Free, Point-of-Care Platform to Diagnose Acute Promyelocytic Leukemia
|
SOHN, LYDIA
|
UNIVERSITY OF CALIFORNIA BERKELEY
|
CA
|
$311,458
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA192176-03
|
|
Developmental studies to inform clinical stratification and targeting of SHH MB
|
JOYNER, ALEXANDRA
|
SLOAN-KETTERING INST CAN RESEARCH
|
NY
|
$449,546
|
|
Pediatric Cancer
|
2018
|
NINDS
|
5R01NS096368-03
|
|
Regulation of Medulloblastoma Metastasis by Emp1
|
WECHSLER-REYA, ROBERT
|
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
|
CA
|
$426,563
|
|
Pediatric Cancer
|
2018
|
NCI
|
1R03CA223730-01
|
|
Genetic underpinnings of ethnic disparities in bone toxicities between Hispanic and non-Hispanic children treated for acute lymphoblastic leukemia
|
YAO, SONG
|
ROSWELL PARK CANCER INSTITUTE CORP
|
NY
|
$87,050
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA178454-07
|
|
The role and functional mechanism of TET1 in MLL-rearranged leukemia
|
CHEN, JIANJUN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
CA
|
$369,725
|
|
Pediatric Cancer
|
2018
|
NCI
|
7R01CA211963-02
|
|
Ionizing radiation induced hematological malignancies
|
ZHOU, DAOHONG
|
UNIVERSITY OF FLORIDA
|
FL
|
$368,866
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA215504-02
|
|
Instructive role of MLL fusion proteins in lineage determination and leukemogenesis
|
THIRMAN, MICHAEL
|
UNIVERSITY OF CHICAGO
|
IL
|
$594,545
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R21CA216551-02
|
|
Targeting DNA Base Excision Repair in Acute Myeloid Leukemias
|
LLOYD, R.
|
OREGON HEALTH & SCIENCE UNIVERSITY
|
OR
|
$167,475
|
|
Pediatric Cancer
|
2018
|
NCI
|
1R03CA223949-01
|
|
O-GlcNAcylation of Ewing sarcoma proteins in chromosomal maintenance
|
AZUMA, MIZUKI
|
UNIVERSITY OF KANSAS LAWRENCE
|
KS
|
$89,000
|
|
Pediatric Cancer
|
2018
|
NCI
|
1R03CA216174-01A1
|
|
Statewide Assessment of HPV Vaccination Among Childhood Cancer Survivors
|
KIRCHHOFF, ANNE
|
UNIVERSITY OF UTAH
|
UT
|
$151,979
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA152108-07
|
|
Molecular and Cellular Mechanisms of Chronic Myelomonocytic Leukemia (CMML)
|
ZHANG, JING
|
UNIVERSITY OF WISCONSIN-MADISON
|
WI
|
$373,634
|
|
Pediatric Cancer
|
2018
|
NHLBI
|
5R01HL117737-19
|
|
Microchimerism as AlloImmunity
|
NELSON, J.
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$443,085
|
|
Pediatric Cancer
|
2018
|
NCI
|
1R01CA215118-01A1
|
|
Stem cell self-renewal programs in rhabdomyosarcoma
|
LANGENAU, DAVID
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$385,444
|
|
Pediatric Cancer
|
2018
|
NCI
|
2R01CA163086-06A1
|
|
Function and targeting of a stable transcription factor complex in leukemia
|
ROEDER, ROBERT
|
ROCKEFELLER UNIVERSITY
|
NY
|
$387,731
|
|
Pediatric Cancer
|
2018
|
NCI
|
1R01CA214812-01A1
|
|
Structure and function of genome plasticity in human cancer
|
KENTSIS, ALEX
|
SLOAN-KETTERING INST CAN RESEARCH
|
NY
|
$497,179
|
|
Pediatric Cancer
|
2018
|
NCI
|
1R01CA215059-01A1
|
|
The Role of DLST in Leukemogenesis
|
FENG, HUI
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
MA
|
$377,437
|
|
Pediatric Cancer
|
2018
|
NCI
|
1R01CA215981-01A1
|
|
Regulation and function of HOX genes in Ewing sarcoma pathogenesis
|
LAWLOR, ELIZABETH
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$387,494
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA193842-04
|
|
Characterizing MSI2 in leukemia
|
KHARAS, MICHAEL
|
SLOAN-KETTERING INST CAN RESEARCH
|
NY
|
$414,827
|
|
Pediatric Cancer
|
2018
|
NCI
|
5K08CA201611-02
|
|
DEFINING THE ROLE OF DOT1L IN DNMT3A-MUTANT LEUKEMIA
|
RAU, RACHEL
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$162,148
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA210911-02
|
|
Targeting the TGIF/Twist1 network in osteosarcoma
|
ATFI, AZEDDINE
|
UNIVERSITY OF MISSISSIPPI MED CTR
|
MS
|
$348,844
|
|
Pediatric Cancer
|
2018
|
NCI
|
1R01CA215651-01A1
|
|
Dual PI3K/BRD4 inhibitory chemotype for maximum inhibition of Myc and cancer
|
DURDEN, DONALD
|
UNIVERSITY OF CALIFORNIA, SAN DIEGO
|
CA
|
$509,469
|
|
Pediatric Cancer
|
2018
|
NHLBI
|
1R01HL136965-01A1
|
|
MRI methods for high resolution imaging of the lung
|
LARSON, PEDER
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
CA
|
$729,639
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R03CA216466-02
|
|
Modeling Mdm2- and 12q amplicon-driven sarcoma
|
MANFREDI, JAMES
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
NY
|
$83,493
|
|
Pediatric Cancer
|
2018
|
NCI
|
5K08CA201640-02
|
|
Developing differentiation therapy for the treatment of patients with acute myeloid leukemia
|
SYKES, DAVID
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$169,268
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA207086-02
|
|
Mechanisms of KLF4 suppression in pediatric leukemia
|
LACORAZZA, DANIEL
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$370,641
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA193235-04
|
|
Metabolic Regulation in Leukemia-Initatiating Cells
|
NAKADA, DAISUKE
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$462,191
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA101774-16
|
|
Mechanisms of Leukemogenesis in Down Syndrome
|
CRISPINO, JOHN
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
IL
|
$337,725
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA199111-34
|
|
Opening of the Blood-Brain Barrier to Antitumor Agents
|
NEUWELT, EDWARD
|
OREGON HEALTH & SCIENCE UNIVERSITY
|
OR
|
$617,175
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA190661-03
|
|
Novel Biomarkers to Risk-Stratify AML Patients with NPM1^Pos/FLT3-IT^Neg Genotype
|
STIREWALT, DEREK
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$580,264
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA180692-04
|
|
Role of LMO1 in Neuroblastoma Initiation and Maintenance
|
MARIS, JOHN
|
CHILDREN'S HOSP OF PHILADELPHIA
|
PA
|
$606,838
|
|
Pediatric Cancer
|
2018
|
NCI
|
5K08CA204734-03
|
|
Determining the Role of BCOR Mutations in Myeloid Malignancies
|
LINDSLEY, ROBERT
|
DANA-FARBER CANCER INST
|
MA
|
$176,970
|
|
Pediatric Cancer
|
2018
|
NCI
|
5UM1CA183730-05
|
|
Collaborative Human Tissue Network (CHTN)
|
RAMIREZ MILAN, NILSA
|
RESEARCH INST NATIONWIDE CHILDREN'S HOSP
|
OH
|
$769,787
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA181231-03
|
|
A high content screen dissecting ciliogenesis and oncogenic Hedgehog signaling
|
REITER, JEREMY
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
CA
|
$488,144
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA211657-02
|
|
Role of long non-coding RNAs in sarcoma pathogenesis
|
SWEET-CORDERO, ERIC
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
CA
|
$400,745
|
|
Pediatric Cancer
|
2018
|
NCI
|
5F30CA217006-02
|
|
Analysis of the novel phenomenon of antibody-mediated fratricide in Acute Myeloid Leukemia
|
FATEHCHAND, KAVIN
|
OHIO STATE UNIVERSITY
|
OH
|
$49,524
|
|
Pediatric Cancer
|
2018
|
NCI
|
5U24CA196173-04
|
|
COG Biospecimen Bank
|
RAMIREZ MILAN, NILSA
|
RESEARCH INST NATIONWIDE CHILDREN'S HOSP
|
OH
|
$2,244,903
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA176803-04
|
|
Targeted- and timed-releasing nanotherapeutics against leukemia stem cells
|
PAN, CHONG-XIAN
|
UNIVERSITY OF CALIFORNIA AT DAVIS
|
CA
|
$359,138
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA177810-04
|
|
Modulation of MicroRNAs with Xenobiotics to Target c-Myc
|
LI, YONG
|
CLEVELAND CLINIC LERNER COM-CWRU
|
OH
|
$362,569
|
|
Pediatric Cancer
|
2018
|
NIGMS
|
5F31GM116569-03
|
|
Developing an Artemis Nuclease Inhibitor to Potentially Treat Acute Lymphoblastic Leukemia
|
ESGUERRA, ZITADEL ANNE
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$43,166
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA133379-10
|
|
The role of the SCF/FBW7 ubiquitin ligase complex in hematopiesis and leukemia.
|
AIFANTIS, IANNIS
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
NY
|
$381,375
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA214965-03
|
|
The role and mechanism of FTO in leukemogenesis and drug response
|
CHEN, JIANJUN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
CA
|
$444,571
|
|
Pediatric Cancer
|
2018
|
NINDS
|
1R21NS101400-01A1
|
|
Paracrine Angiotensin II Signaling Promotes Medulloblastoma through MYC Activation
|
YING, MINGYAO
|
HUGO W. MOSER RES INST KENNEDY KRIEGER
|
MD
|
$242,573
|
|
Pediatric Cancer
|
2018
|
NCI
|
5U10CA180886-05
|
|
COG NCTN Network Group Operations Center
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
PA
|
$20,853,800
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA201235-02
|
|
Targeting the GFI1-LSD1 Axis in T-Cell Acute Lymphoblastic Leukemia
|
ENGEL, MICHAEL
|
UNIVERSITY OF UTAH
|
UT
|
$348,273
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA217092-02
|
|
Mechanisms of Formation and Progression of Preleukemic Stem Cells
|
STEIDL, ULRICH
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
NY
|
$397,371
|
|
Pediatric Cancer
|
2018
|
NIMHD
|
5R01MD007801-05
|
|
Reducing racial/ethnic inequities in childhood cancer survivorship
|
MILAM, JOEL
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$412,142
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA148688-07
|
|
The ALK receptor tyrosine kinase as a therapeutic target in neuroblastoma
|
GEORGE, RANI
|
DANA-FARBER CANCER INST
|
MA
|
$413,844
|
|
Pediatric Cancer
|
2018
|
NCI
|
1R01CA215518-01A1
|
|
Targeting the Notch:Myc axis in leukemia/lymphoma
|
PEAR, WARREN
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$468,293
|
|
Pediatric Cancer
|
2018
|
NCI
|
5K12CA090433-17
|
|
Pediatric Oncology Clinical Research Training Program
|
BLANEY, SUSAN
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$827,164
|
|
Pediatric Cancer
|
2018
|
NINDS
|
5R01NS088355-04
|
|
Targeting BET-bromodomains in neuroblastoma
|
WEISS, WILLIAM
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
CA
|
$651,177
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA201496-03
|
|
Novel RNA-Directed Therapy for the Treatment of Acute Myeloid Leukemia
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
CA
|
$479,954
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA196851-03
|
|
Targeting vismodegib-resistant tumors using BH3 mimetics
|
KIM, JAMES
|
UT SOUTHWESTERN MEDICAL CENTER
|
TX
|
$346,985
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA215489-02
|
|
MYB family alterations in pediatric gliomas
|
LIGON, KEITH
|
DANA-FARBER CANCER INST
|
MA
|
$554,504
|
|
Pediatric Cancer
|
2018
|
NCI
|
5UM1CA081457-20
|
|
Pediatric Brain Tumor Consortium (PBTC)
|
ONAR-THOMAS, ARZU
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$2,711,850
|
|
Pediatric Cancer
|
2018
|
NHLBI
|
5F30HL132613-04
|
|
Characterizing the Novel Protein C15orf65
|
HOWE, RUTH
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
NY
|
$49,524
|
|
Pediatric Cancer
|
2018
|
NHLBI
|
5R01HL131444-03
|
|
The role of EVI1-induced hypermethylation in leukemogenesis.
|
QIAN, ZHIJIAN
|
UNIVERSITY OF ILLINOIS AT CHICAGO
|
IL
|
$399,750
|
|
Pediatric Cancer
|
2018
|
NIDDK
|
5R01DK061470-15
|
|
Surgical Studies on the Role on Gastrin-releasing Peptide in Neuroblastoma
|
CHUNG, DAI
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
TN
|
$409,278
|
|
Pediatric Cancer
|
2018
|
NCI
|
5F31CA213926-02
|
|
Omics Approach to Interrogating Mechanism of ETV5 in Glioma
|
PARK, HANNAH
|
CEDARS-SINAI MEDICAL CENTER
|
CA
|
$38,124
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA215452-02
|
|
Identifying and targeting oncogenic Myc enhancer control in pediatric tumors
|
LIN, CHARLES
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$362,569
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA215610-02
|
|
ABT-199 based therapies to treat neuroblastoma
|
FABER, ANTHONY
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
VA
|
$359,846
|
|
Pediatric Cancer
|
2018
|
NCI
|
1R01CA225231-01
|
|
Identification of therapeutic targets for leukemia stem cells in AML-iPSC models
|
PAPAPETROU, EIRINI
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
NY
|
$625,414
|
|
Pediatric Cancer
|
2018
|
NICHD
|
5R01HD081123-04
|
|
Personalized Whole Body Staging for Children with Cancer: A Solution to the Conundrum of Long-Term Side Effects from CT and PET/CT Scans
|
DALDRUP-LINK, HEIKE
|
STANFORD UNIVERSITY
|
CA
|
$492,552
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA206210-03
|
|
Therapeutic targeting of glutamine metabolism in MDS
|
KONOPLEVA, MARINA
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$496,810
|
|
Pediatric Cancer
|
2018
|
NICHD
|
5R01HD083930-03
|
|
Cryopreservation and Transplantation of Ovarian Cortical Tissue for Fertility Preservation
|
ZELINSKI, MARY
|
OREGON HEALTH & SCIENCE UNIVERSITY
|
OR
|
$588,107
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA216344-02
|
|
Defining the non-myogenic origins of pediatric rhabdomyosarcoma
|
HATLEY, MARK
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$410,606
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA211996-02
|
|
Dexrazoxane and Prevention of Anthracycline-Related Cardiomyopathy
|
CHOW, ERIC
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$646,503
|
|
Pediatric Cancer
|
2018
|
NHLBI
|
5K08HL136894-02
|
|
Hedgehog Signaling in the Progression of Myelodysplastic Syndromes
|
GONDEK, LUKASZ
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$171,720
|
|
Pediatric Cancer
|
2018
|
NCI
|
1R41CA224830-01
|
|
Preclinical studies of Selective and Orally Bioavailable Aurora B Inhibitors for the Treatment of AML
|
LI, HONG YU
|
SYNACTIX PHARMACEUTICALS, INC.
|
AZ
|
$299,975
|
|
Pediatric Cancer
|
2018
|
NCI
|
5P30CA013148-46
|
8603
|
04 Neuro-Oncology Program
|
GILLESPIE, G.
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
AL
|
$96,888
|
|
Pediatric Cancer
|
2018
|
NCI
|
1F30CA224971-01
|
|
Perturbation of Polycomb-mediated gene repression by histone H3 mutations.
|
WEINBERG, DANIEL
|
WEILL MEDICAL COLL OF CORNELL UNIV
|
NY
|
$49,524
|
|
Pediatric Cancer
|
2018
|
NHLBI
|
1F31HL137310-01A1
|
|
The TIFAB-USP15 Complex in the Pathogenesis of MDS and AML
|
NIEDERKORN, MADELINE
|
UNIVERSITY OF CINCINNATI
|
OH
|
$32,864
|
|
Pediatric Cancer
|
2018
|
NCI
|
1R01CA219024-01A1
|
|
Clinical significance and mechanism of action of exosomal microRNAs in Neuroblastoma chemoresistance.
|
FABBRI, MULLER
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
CA
|
$123,772
|
|
Pediatric Cancer
|
2018
|
NCI
|
1U01CA224766-01
|
|
Protective Role of Nonclassical Monocytes in Immunotherapies for Solid Cancers
|
HEDRICK, CATHERINE
|
LA JOLLA INST FOR ALLERGY & IMMUNOLGY
|
CA
|
$418,320
|
|
Pediatric Cancer
|
2018
|
NCI
|
5T32CA009351-40
|
|
Pediatric Oncology Research Training Program
|
BERNSTEIN, IRWIN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$250,143
|
|
Pediatric Cancer
|
2018
|
NHLBI
|
5K08HL127269-04
|
|
Bone Marrow Microenvironmental Expression of Cytochrome P450 Enzymes
|
GHIAUR, GABRIEL
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$171,720
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA216354-02
|
|
Late Effects Prediction using Clinical Phenotypes and Whole Genome Sequencing
|
YASUI, YUTAKA
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$716,706
|
|
Pediatric Cancer
|
2018
|
NHLBI
|
5R01HL052725-24
|
|
Molecular Pathogenesis of Fanconi Anemia
|
D'ANDREA, ALAN
|
DANA-FARBER CANCER INST
|
MA
|
$400,792
|
|
Pediatric Cancer
|
2018
|
NHLBI
|
5K08HL132101-03
|
|
Early Clonal Evolution in Acquired Aplastic Anemia
|
BABUSHOK, DARIA
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$169,776
|
|
Pediatric Cancer
|
2018
|
NHLBI
|
5R01HL128173-04
|
|
Multiscale Modeling of Myelodysplastic Syndromes
|
COREY, SETH
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
VA
|
$713,684
|
|
Pediatric Cancer
|
2018
|
NINDS
|
5R01NS085336-05
|
|
Pediatric low-grade gliomas: biology and molecular targeting.
|
RESNICK, ADAM
|
CHILDREN'S HOSP OF PHILADELPHIA
|
PA
|
$367,500
|
|
Pediatric Cancer
|
2018
|
NINDS
|
5R01NS049251-12
|
|
Multimodal Registration of the Brain's Cortical Surface
|
MIGA, MICHAEL
|
VANDERBILT UNIVERSITY
|
TN
|
$733,330
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA098571-14
|
|
Molecular Mechanisms of eIF4E mediated transformation
|
BORDEN, KATHERINE
|
UNIVERSITY OF MONTREAL
|
CANADA
|
$227,057
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA197991-03
|
|
Determining the Role of Metabolism in Resistance in Acute Myeloid Leukemia
|
PARDEE, TIMOTHY
|
WAKE FOREST UNIVERSITY HEALTH SCIENCES
|
NC
|
$354,563
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA173852-05
|
|
Role of p21 activated kinase in Leukemogenesis
|
KAPUR, REUBEN
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
IN
|
$323,700
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R25CA023944-35
|
|
PEDIATRIC ONCOLOGY EDUCATION (YEARS 33 - 37)
|
GRONEMEYER, SUZANNE
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$321,271
|
|
Pediatric Cancer
|
2018
|
NCI
|
5U01CA176063-05
|
|
ARID5B and disparities of childhood leukemia
|
YANG, JUN
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$368,510
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA172443-05
|
|
Targeting NEDD8-Mediated Protein Turnover in AML
|
CAREW, JENNIFER
|
UNIVERSITY OF ARIZONA
|
AZ
|
$286,661
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA175353-05
|
|
Deep sequencing for minimal residual disease detection in Acute Lymphoblastic Leu
|
ROBINS, HARLAN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$544,480
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA178030-05
|
|
Regulation of transcription and tumor suppression by MTG family members
|
HIEBERT, SCOTT
|
VANDERBILT UNIVERSITY
|
TN
|
$364,000
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA194923-04
|
|
Long non-coding RNAs in hematopoiesis and blood malignancy
|
AIFANTIS, IANNIS
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
NY
|
$457,533
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R21CA208937-02
|
|
Mechanism-based approach to combine histone deacetylase inhibitors with PARP inhibitors for therapy in AML
|
RASSOOL, FEYRUZ
|
UNIVERSITY OF MARYLAND BALTIMORE
|
MD
|
$168,019
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA193776-04
|
|
Improving risk allocation and developing novel therapies for children with T-ALL
|
TEACHEY, DAVID
|
CHILDREN'S HOSP OF PHILADELPHIA
|
PA
|
$594,741
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA193890-04
|
|
HAUSP inhibitors in p53-wild type and p53-mutant tumors
|
GU, WEI
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$366,000
|
|
Pediatric Cancer
|
2018
|
NCI
|
5U54CA193419-04
|
7381
|
Project 2: Molecular Modulation of Chromatin and Nuclear Structure in Cancer
|
LICHT, JONATHAN
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
IL
|
$677,567
|
|
Pediatric Cancer
|
2018
|
NCI
|
5K07CA200668-03
|
|
Patient Preferences and Adherence in Adolescents and Young Adults with Cancer
|
MCGRADY, MEGHAN
|
CINCINNATI CHILDRENS HOSP MED CTR
|
OH
|
$144,855
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA132946-11
|
|
Pharmacogenomics of Ara-C in AML
|
LAMBA, JATINDER
|
UNIVERSITY OF FLORIDA
|
FL
|
$310,602
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA172723-06
|
|
Predicting deficits in social competence for pediatric brain tumor survivors
|
VANNATTA, KATHRYN
|
RESEARCH INST NATIONWIDE CHILDREN'S HOSP
|
OH
|
$223,065
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R21CA205106-02
|
|
A novel VLP vaccine to prevent EBV infection and EBV - associated malignancies
|
OGEMBO, JAVIER
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
CA
|
$176,605
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA206019-03
|
|
Host factors, tumor microenvironment and survival in a multiethnic study of Hodgkin lymphoma patients
|
COZEN, WENDY
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$802,716
|
|
Pediatric Cancer
|
2018
|
NINR
|
5R01NR015458-04
|
|
Building Evidence for Effective Palliative/End of Life Care for Teens with Cancer
|
LYON, MAUREEN
|
CHILDREN'S RESEARCH INSTITUTE
|
DC
|
$662,331
|
|
Pediatric Cancer
|
2018
|
NCI
|
5P30CA042014-29
|
5852
|
Clinical Protocol and Data Management
|
AKERLEY, WALLACE
|
UNIVERSITY OF UTAH
|
UT
|
$223,588
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R21CA215867-02
|
|
PQ6: Role of Cellular Senescence in Late Effects of Childhood Cancer Therapy
|
BRAM, RICHARD
|
MAYO CLINIC ROCHESTER
|
MN
|
$172,913
|
|
Pediatric Cancer
|
2018
|
NCI
|
5U10CA180899-05
|
|
Children's Oncology Group Statistics and Data Center
|
DEVIDAS, MEENAKSHI
|
UNIVERSITY OF FLORIDA
|
FL
|
$7,738,106
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA175761-05
|
|
Function of the PR domain of the MDSI-EVI1 in MLL fusion protein leukemogenesis
|
PERKINS, ARCHIBALD
|
UNIVERSITY OF ROCHESTER
|
NY
|
$318,513
|
|
Pediatric Cancer
|
2018
|
NCI
|
5F31CA217140-02
|
|
Novel mechanisms and therapeutic strategies of refractory leukemia
|
MELGAR, KATELYN
|
CINCINNATI CHILDRENS HOSP MED CTR
|
OH
|
$37,204
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA174851-05
|
|
A longitudinal assessment of frailty in young adult survivors of childhood cancer
|
NESS, KIRSTEN
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$511,226
|
|
Pediatric Cancer
|
2018
|
NCI
|
5U54CA193461-04
|
7298
|
Project 1: Clonal Dynamics Guiding Curative Therapies for Acute Myeloid Leukemia
|
SCADDEN, DAVID
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$366,060
|
|
Pediatric Cancer
|
2018
|
NHLBI
|
5R01HL079571-14
|
|
A Vital tool for the Study of DBA: The Diamond Blackfan Anemia Registry
|
LIPTON, JEFFREY
|
FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
|
NY
|
$420,957
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R33CA214333-02
|
|
Integrated exosomes profiling for minimally invasive diagnosis and monitoring of cancer
|
ZENG, YONG
|
UNIVERSITY OF KANSAS LAWRENCE
|
KS
|
$380,938
|
|
Pediatric Cancer
|
2018
|
NHLBI
|
5R01HL126947-04
|
|
Epigenetic biomarkers of response to Azacytidine in Myelodysplastic Syndromes
|
FIGUEROA, MARIA
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
FL
|
$389,800
|
|
Pediatric Cancer
|
2018
|
NCI
|
2P50CA100632-16
|
7425
|
Project 2: Anti-PR1 Immune Therapy for Myeloid Leukemia
|
MOLLDREM, JEFFREY
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$238,193
|
|
Pediatric Cancer
|
2018
|
NCI
|
2P50CA100632-16
|
7427
|
Project 4: Off-the-shelf engineered cord blood-derived natural killer cells for the treatment acute lymphoblastic leukemia
|
REZVANI, KATY
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$238,194
|
|
Pediatric Cancer
|
2018
|
NCI
|
2P50CA100632-16
|
7428
|
Project 5: Targeting Oxidative Phosphorylation in AML
|
DRAETTA, GIULIO
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
TX
|
$215,115
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R00CA175184-04
|
|
A role for notch in self renewal in embryonal rhabdomyosarcoma
|
IGNATIUS, MYRON
|
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
|
TX
|
$249,000
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA185058-05
|
|
Impact of low IL-10 levels at birth and leukemia risk
|
KOGAN, SCOTT
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
CA
|
$602,331
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA064140-25
|
|
Role of AML1-ETO in Acute Leukemia
|
HIEBERT, SCOTT
|
VANDERBILT UNIVERSITY
|
TN
|
$353,250
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA185687-04
|
|
Risk of Pediatric and Adolescent Cancer Associated with Medical Imaging
|
SMITH-BINDMAN, REBECCA
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
CA
|
$2,139,085
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA188516-05
|
|
Cooperating Pathways in Gliomagenesis
|
BAKER, SUZANNE
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$372,463
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA196882-03
|
|
Characterizing Histone Deacetylases in Rhabdomyosarcoma
|
CHEN, ELEANOR
|
UNIVERSITY OF WASHINGTON
|
WA
|
$318,077
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA200574-03
|
|
Tumor-Targeted Chemo-Immunotherapy for Osteosarcoma Metastasis
|
ZHANG, LIANGFANG
|
UNIVERSITY OF CALIFORNIA, SAN DIEGO
|
CA
|
$359,138
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA140198-10
|
|
Targeting Oncogenic ALK Signaling in Neuroblastoma
|
MOSSE, YAEL
|
CHILDREN'S HOSP OF PHILADELPHIA
|
PA
|
$374,304
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA174808-06
|
|
Targeting the G-CSF/STAT3 signaling pathway in neuroblastoma cancer stem cells
|
SHOHET, JASON
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
MA
|
$347,563
|
|
Pediatric Cancer
|
2018
|
NCI
|
5R01CA190509-04
|
|
The function of cyclin C in tumorigenesis
|
SICINSKI, PETER
|
DANA-FARBER CANCER INST
|
MA
|
$453,569
|
|
